CJC-1295 and Ipamorelin combine GHRH- and GHRP-based pathways to create a dual-action GH-release research model. Studies use this pairing to explore pulsatile GH signaling, tissue-support behavior, and metabolic efficiency patterns in controlled non-clinical environments. For research use only.